Role of nintedanib in the treatment of progressive pulmonary fibrosis (PPF) in daily clinical practice.

被引：0
|
作者：
Andres Franch, Fatima [1 ]
Alvarez Martinez, Ignacio Salvador [2 ]
Andujar Llamazares, Mario [3 ]
Segura Ayala, Daniel [3 ]
Meneses Petersen, Elsie Daviana [1 ]
Cabanes Lopez, Luis [1 ]
Novella Sanchez, Laura [1 ]
Ferrando Gabarda, Jose Ramon [1 ]
Meseguer Sisternes, Maria [1 ]
Lluch Tortajada, Inmaculada [1 ]
Naval Sendra, Elsa [1 ]
机构：
[1] Hosp Univ La Ribera, Resp Med Unit, Alzira, Valencia, Spain
[2] Hosp Univ La Ribera, Internal Med Unit, Alzira, Valencia, Spain
[3] Hosp Gen Univ Castellon, Resp Med Unit, Castellon de La Plana, Spain
来源：
EUROPEAN RESPIRATORY JOURNAL | 2023年 / 62卷
关键词：
D O I：
10.1183/13993003.congress-2023.PA407
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Progressive pulmonary fibrosis (PPF)
    Duman, Dildar
    TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, 2022, 70 (04): : 375 - 381
  • [2] Meta-analysis of effect of nintedanib on mortality in subjects with idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis ( PPF)
    Wuyts, Wim A.
    Maher, Toby M.
    Wijsenbeek, Marlies
    Koschel, Dirk
    Martinez, Fernando J.
    Stansen, Wibke
    Stowasser, Susanne
    Richeldi, Luca
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [3] Meta-analysis of effect of nintedanib on mortality in subjects with idiopathic pulmonary fibrosis (IPF) and other forms of progressive pulmonary fibrosis (PPF)
    Koschel, D.
    Wuyts, W.
    Maher, T.
    Wijsenbeek, M.
    Martinez, F.
    Stansen, W.
    Stowasser, S.
    Richeldi, L.
    PNEUMOLOGIE, 2024, 78 : S81 - S82
  • [4] Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
    Fletcher, Sophie V.
    Jones, Mark G.
    Renzoni, Elizabeth A.
    Parfrey, Helen
    Hoyles, Rachel K.
    Spinks, Katherine
    Kokosi, Maria
    Kwok, Apollinaris
    Warburton, Chris
    Titmuss, Vanessa
    Thillai, Muhunthan
    Simler, Nicola
    Maher, Toby M.
    Brereton, Christopher J.
    Chua, Felix
    Wells, Athol U.
    Richeldi, Luca
    Spencer, Lisa G.
    ERJ OPEN RESEARCH, 2018, 4 (04)
  • [5] Study Design and Rationale for the TETON-PPF Clinical Trial of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
    Nathan, S. D.
    Behr, J.
    Cottin, V.
    Lancaster, L. H.
    Smith, P.
    Rao, Y.
    Breytenbach, N.
    Bell, H.
    Peterson, L.
    Flaherty, K. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [6] Counselling and consenting patients to start nintedanib for progressive pulmonary fibrosis (PPF) in a group setting: results from a patient feedback survey
    Zakis, Katie
    Morris, Helen
    Swale, Jenna
    Barker, Annie
    Waye, Rebecca
    Newman, Kate
    Garfoot, Theresa
    Montgomery, Holly
    Rivera-Ortega, Pilar
    Johnston, Janet
    Hayton, Conal
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [7] Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis
    Wijsenbeek, Marlies
    Swigris, Jeffrey J.
    Inoue, Yoshikazu
    Kreuter, Michael
    Maher, Toby M.
    Suda, Takafumi
    Baldwin, Michael
    Mueller, Heiko
    Rohr, Klaus B.
    Flaherty, Kevin R.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 63 (02)
  • [8] Progressive Pulmonary Fibrosis (PPF) in Patients with exogenous allergic Alveolitis
    Walscher, J.
    Theegarten, D.
    Boerner, E.
    Jehn, L.
    Costabel, U.
    Bonella, F.
    PNEUMOLOGIE, 2023, 77 : S102 - S102
  • [9] Nintedanib for the treatment of idiopathic pulmonary fibrosis
    Varone, Francesco
    Sgalla, Giacomo
    Iovene, Bruno
    Bruni, Teresa
    Richeldi, Luca
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (02) : 167 - 175
  • [10] Pirfenidone vs nintedanib for treatment of idiopathic pulmonary fibrosis in clinical practice: efficacy, tolerability, and adverse effects
    Sadon, Amal A. E-A
    Kenawy, Ahmed S.
    Abdelsalam, Ashraf H.
    Attia, Hosam M.
    EGYPTIAN JOURNAL OF CHEST DISEASES AND TUBERCULOSIS, 2020, 69 (03): : 549 - 559
12345